GET DAILY SIGNALSWhy Is Profound Medical Corp. (PROF) Stock Down -3.49% Today?
Key Takeaways
- PROF shares fell about 3.49% to $6.64 in early trading, extending losses after a disappointing post-earnings reaction.
- The primary catalyst is the company's third-quarter results, which topped revenue estimates but missed on the bottom line while raising questions about revenue quality.
- Secondary drivers include a planned CEO transition and scrutiny of the pace of recurring revenue growth and cash burn.
- The move is earnings-driven, with the stock now trading below its 200-day moving average as broader healthcare momentum offers little support.
- Traders are watching upcoming CAPTAIN trial data at RSNA, 2027 CMS reimbursement, and utilization of the company's installed base.
- Explore detailed Price Targets, Earnings, and Forecast pages for deeper analysis on this ticker.
- For AI-driven trading ideas across thousands of tickers, explore Trending AI Robots.
Opening Summary
Profound Medical Corp. (PROF), a commercial-stage medical device company that develops MRI-guided, incision-free therapeutic systems for ablating diseased prostate tissue, saw its stock trade lower in today's session. Shares were down roughly 3.49% at $6.64, compared with a prior closing price of $6.88. The decline follows the company's third-quarter earnings report, released after the previous session's close, which delivered record revenue but an earnings miss and a more cautious read on the underlying business.
Earnings Results: A Revenue Beat Overshadowed by an EPS Miss
The market's immediate reaction centered on Profound Medical's third-quarter 2026 results. The company reported total revenue of approximately $9.8 million, up about 86% year over year and narrowly ahead of consensus estimates. Gross margin held firm at 78%, up from 74% a year earlier. However, the net loss of $0.21 per share missed the consensus estimate of a $0.19 loss, and operating expenses rose 21% to $15.5 million on higher headcount, commissions, and cost-reduction R&D spending.
Beyond the headline figures, investors focused on the quality of the revenue growth. A meaningful portion of capital equipment shipments that slipped from the second quarter into the third inflated the year-over-year comparison, while recurring non-capital revenue was essentially flat against the prior-year period. For a company whose growth story depends on converting system placements into recurring procedure revenue, that flattening drew scrutiny and contributed to the negative market reaction.
Guidance and Cash Considerations
Management reiterated a full-year 2026 revenue outlook of at least $25 million, with gross margin expected at 70% or higher. While framed as a positive, the implied fourth-quarter revenue of roughly $7.4 million suggested a sequential slowdown that some analysts viewed as a headwind. The company also reported approximately $33.3 million in cash at quarter-end, down from earlier levels, even as operating cash use improved sharply on a sequential basis. The shrinking cash position and the ongoing path to profitability remained central concerns for investors.
Leadership Transition and Commercial Developments
The quarter also brought corporate announcements that added to the narrative. Richard Fabian, currently President, is set to succeed Dr. Arun Menawat as Chief Executive Officer effective January 14, 2027, with Dr. Menawat assuming the role of Executive Chairman. A planned transition of this nature can introduce a measure of execution uncertainty. On the commercial front, the company recently entered a supply and distribution agreement with Cook Medical to expand U.S. sales of its TULSA-PRO system, though the material impact is not expected until the second half of 2027.
Market Context and Trading Activity
The move in PROF reflects an earnings-driven decline rather than broad sector weakness. With a relatively modest average daily volume, the stock's intraday range has remained wide, and shares are now trading below their 200-day moving average, a technical level that can reinforce selling pressure. The stock had rallied into the report, so the post-earnings slide also reflects a degree of profit-taking and a reset of expectations following a run-up ahead of the announcement.
What Comes Next for PROF
Looking ahead, investors will watch for one-year CAPTAIN trial data expected at the RSNA meeting in early December, which could provide clinical validation for the TULSA procedure. The 2027 CMS reimbursement environment and the ramp of the Cook Medical distribution channel are additional catalysts. Key risks include the pace of conversion of the company's growing installed base into recurring revenue, continued cash consumption, competitive pressure from well-funded robotic entrants in prostate care, and execution risk surrounding the leadership handoff.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots, drawn from hundreds of available bots covering thousands of tickers. Only the strongest performers under current market conditions are featured. Bots vary by strategy, timeframe, performance metrics, and the symbols they trade, offering traders a way to explore systematic approaches to market opportunities. Explore the page to see which strategies are currently leading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PROF's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for PROF turned positive on October 30, 2026. Looking at past instances where PROF's MACD turned positive, the stock continued to rise in 34 of 42 cases over the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on PROF as a result. In 63 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
PROF moved above its 50-day moving average on October 30, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PROF crossed bullishly above the 50-day moving average on November 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 63%.
Following a +6.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where PROF advanced for three days, in 197 of 258 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 112 of 149 cases where PROF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
Bearish Trend Analysis
The 10-day RSI Indicator for PROF moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In 30 of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PROF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
PROF broke above its upper Bollinger Band on November 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. PROF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.047) is normal, around the industry mean (4.115). P/E Ratio (-6.949) is within average values for comparable stocks, (1.586). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (10.194) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 48 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PROF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer and manufacturee of therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology
Industry MedicalNursingServices